38 related articles for article (PubMed ID: 36458938)
1. CRISPR-Cas9 screens identify regulators of antibody-drug conjugate toxicity.
Tsui CK; Barfield RM; Fischer CR; Morgens DW; Li A; Smith BAH; Gray MA; Bertozzi CR; Rabuka D; Bassik MC
Nat Chem Biol; 2019 Oct; 15(10):949-958. PubMed ID: 31451760
[TBL] [Abstract][Full Text] [Related]
2. Macrolide and Ketolide Antibiotics Inhibit the Cytotoxic Effect of Trastuzumab Emtansine in HER2-Positive Breast Cancer Cells: Implication of a Potential Drug-ADC Interaction in Cancer Chemotherapy.
Kiyomiya K; Tomabechi R; Saito N; Watai K; Takada T; Shirasaka Y; Kishimoto H; Higuchi K; Inoue K
Mol Pharm; 2023 Dec; 20(12):6130-6139. PubMed ID: 37971309
[TBL] [Abstract][Full Text] [Related]
3. SLC46A3 is a lysosomal proton-coupled steroid conjugate and bile acid transporter involved in transport of active catabolites of T-DM1.
Tomabechi R; Kishimoto H; Sato T; Saito N; Kiyomiya K; Takada T; Higuchi K; Shirasaka Y; Inoue K
PNAS Nexus; 2022 Jul; 1(3):pgac063. PubMed ID: 36741448
[TBL] [Abstract][Full Text] [Related]
4. SLC46A3 Is Required to Transport Catabolites of Noncleavable Antibody Maytansine Conjugates from the Lysosome to the Cytoplasm.
Hamblett KJ; Jacob AP; Gurgel JL; Tometsko ME; Rock BM; Patel SK; Milburn RR; Siu S; Ragan SP; Rock DA; Borths CJ; O'Neill JW; Chang WS; Weidner MF; Bio MM; Quon KC; Fanslow WC
Cancer Res; 2015 Dec; 75(24):5329-40. PubMed ID: 26631267
[TBL] [Abstract][Full Text] [Related]
5. SLC46A3 as a Potential Predictive Biomarker for Antibody-Drug Conjugates Bearing Noncleavable Linked Maytansinoid and Pyrrolobenzodiazepine Warheads.
Kinneer K; Meekin J; Tiberghien AC; Tai YT; Phipps S; Kiefer CM; Rebelatto MC; Dimasi N; Moriarty A; Papadopoulos KP; Sridhar S; Gregson SJ; Wick MJ; Masterson L; Anderson KC; Herbst R; Howard PW; Tice DA
Clin Cancer Res; 2018 Dec; 24(24):6570-6582. PubMed ID: 30131388
[TBL] [Abstract][Full Text] [Related]
6. A Novel HER2-targeted Antibody-drug Conjugate Offers the Possibility of Clinical Dosing at Trastuzumab-equivalent Exposure Levels.
Barfield RM; Kim YC; Chuprakov S; Zhang F; Bauzon M; Ogunkoya AO; Yeo D; Hickle C; Pegram MD; Rabuka D; Drake PM
Mol Cancer Ther; 2020 Sep; 19(9):1866-1874. PubMed ID: 32651200
[TBL] [Abstract][Full Text] [Related]
7. Identification of 5-Carboxyfluorescein as a Probe Substrate of SLC46A3 and Its Application in a Fluorescence-Based In Vitro Assay Evaluating the Interaction with SLC46A3.
Tomabechi R; Miyasato M; Sato T; Takada T; Higuchi K; Kishimoto H; Shirasaka Y; Inoue K
Mol Pharm; 2023 Jan; 20(1):491-499. PubMed ID: 36458938
[TBL] [Abstract][Full Text] [Related]
8. HER2-Overexpressing/Amplified Breast Cancer as a Testing Ground for Antibody-Drug Conjugate Drug Development in Solid Tumors.
Pegram MD; Miles D; Tsui CK; Zong Y
Clin Cancer Res; 2020 Feb; 26(4):775-786. PubMed ID: 31582515
[TBL] [Abstract][Full Text] [Related]
9. Novel HER2-Targeting Antibody-Drug Conjugates of Trastuzumab Beyond T-DM1 in Breast Cancer: Trastuzumab Deruxtecan(DS-8201a) and (Vic-)Trastuzumab Duocarmazine (SYD985).
Xu Z; Guo D; Jiang Z; Tong R; Jiang P; Bai L; Chen L; Zhu Y; Guo C; Shi J; Yu D
Eur J Med Chem; 2019 Dec; 183():111682. PubMed ID: 31563805
[TBL] [Abstract][Full Text] [Related]
10. Ado-trastuzumab emtansine: a HER2-positive targeted antibody-drug conjugate.
Corrigan PA; Cicci TA; Auten JJ; Lowe DK
Ann Pharmacother; 2014 Nov; 48(11):1484-93. PubMed ID: 25082874
[TBL] [Abstract][Full Text] [Related]
11.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
